poisar

Stocks · News reference

Eli Lilly Takes 19.9% Stake In TRex Bio With 5.48M Shares, Investing $12.3M In IPO

Benzinga Newsdesk

The Reporting Person beneficially owns an aggregate of 5,480,872 shares of Common Stock of the Issuer, consisting of (a) 2,510,411 shares of Common Stock that were issued to the Reporting Person upon conversion of

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LLYTRXB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Prosper Junior Bakiny

    Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

    Eli Lilly's pipeline extends beyond its blockbuster weight-loss drug Zepbound, with three promising medicines poised to drive future growth: Foundayo (oral GLP-1 for weight loss), Onswik (once-weekly basal insulin for diabetes), and retatrutide (investigational triple-hormone weight-loss drug showing 28.3% average weight loss). These drugs target different patient segments and indications, positioning Eli Lilly to maintain market leadership despite increasing competition.

    LLYNVO
  2. Matthew Benjamin

    Novo Nordisk and Eli Lilly Just Got Some Fantastic News

    A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.

    NVOLLYMRK
  4. SEC EDGAR

    8-K filing — TRex Bio, Inc. (TRXB)

    Filed: 2026-10-13 AccNo: 0001193125-26-420588 Size: 440 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

    TRXB